tetomilast   Click here for help

GtoPdb Ligand ID: 9877

Synonyms: compound 19f [PMID: 7830278] | OPC-6535 | OPC6535
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Tetomilast is a PDE4 inhibitor. Inhibition of PDE4 blocks the oxidative burst in human neutrophils, which is a major mediator of tissue injury in inflammatory diseases. Tetomilast (OPC-6535) was originally identified as an inhibitor of superoxide production by human neutrophils [1]. The clinical potential of PDE4 inhibition in inflammatory bowel disease was reviewed by Salari and Abdollahiin 2012 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 109.78
Molecular weight 370.1
XLogP 1.21
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCOc1cc(ccc1OCC)c1scc(n1)c1cccc(n1)C(=O)O
Isomeric SMILES CCOc1cc(ccc1OCC)c1scc(n1)c1cccc(n1)C(=O)O
InChI InChI=1S/C19H18N2O4S/c1-3-24-16-9-8-12(10-17(16)25-4-2)18-21-15(11-26-18)13-6-5-7-14(20-13)19(22)23/h5-11H,3-4H2,1-2H3,(H,22,23)
InChI Key XDBHURGONHZNJF-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Tetomilast (OPC-6535) has completed clinical trials for several inflammatory indications: ulcerative colitis (Phase 3 NCT00064454), Crohn's disease (Phase 2/3 Phase 2 NCT00989573) and COPD (Phase 3 NCT00874497 was terminated by the study sponsor, Otsuka Pharmaceutical). Phase 2 results from a trial in ulcerative colitis patients were reported in 2007 [3]. Whilst primary end points were not met in this study, secondary end points did indicate potential clinical activity.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Tetomilast-mediated inhibition of PDE4 blunts the proinflammatory functions of leukocytes such as superoxide production and cytokine release.